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Here, I consider whether radiation sensitive individuals might exist in the population and 
the potential impact of low dose/dose rate radiation exposure.  Radiation induces DNA 
double strand breaks (DSBs), which cause lethality if unrepaired and enhance genomic 
instability if misrepaired. DNA damage response (DDR) mechanisms play a vital role in 
protecting cells from the harmful effects of DSB formation. The DDR response 
encompasses DSB repair pathways, of which DNA non homologous end-joining is the 
most significant, and a signal transduction process involving ATM.  Patients defective in 
DDR proteins have been described and some have shown clinical radiosensitivity. 
However, such patients are rare and belong to defined syndromes. The critical question is 
whether heterozygosity or mild defects in DDR proteins confer low dose radiosensitivity. 
Whilst it is unlikely that low dose radiation will dramatic enhance cell killing in 
individuals such patients, it is possible that there could be an impact on stem cell turnover 
leading to stem cell depletion with age. More importantly, it is likely that such patients 
could have increased misrepair of radiation damage and hence an elevated risk of 
radiation induced carcinogenesis. Evidence in support of this and the potentially 
important genes in this context are discussed. 
The potentially harmful impact of low dose radiation damage. 
 
Radiation induces a range of cellular damage, of which DNA damage is the most 
significant. Of the DNA lesions induced by radiation, a DNA double strand break (DSB), 
although not the most abundant lesion, is the most biologically significant. DSBs can be 
directly induced by radiation but can also arise indirectly following repair or replication 
of other lesions. Thus, here my focus will lie on the cellular mechanisms that respond to 
DSBs and the potential consequence of low level DSB formation. Following exposure to 
high doses of radiation, such as following accidental exposure or radiotherapy, 
individuals can show early acute hypersensitivity resulting from the inability of tissue 
stem cells to proliferate and maintain the physiological function of the organs, or more 
delayed hypersensitivity, which can potentially arise from tissue damage arising from an 
elevated inflammatory or cytokine signaling response. Clearly, impaired DSB response 
mechanisms represent one contributing process to both acute and delayed 
hypersensitivity. Hypersensitivity to low dose radiation exposure is less well understood 
but could potentially arise from impaired DNA damage responses or tissue damage. Here, 
I will focus on the potential hypersensitivity of individuals with impaired DNA damage 
response (DDR) mechanisms to low dose radiation exposure. In response to high 
radiation doses, the impact of radiation induced cell death is the most significant outcome 
for consideration. Whilst chronic low dose exposure could potentially also result in cell 
death and/or cellular senescence, another significant outcome for consideration is the 
onset of carcinogenesis. The potential hypersensitivity of individuals to carcinogenesis 
following low dose exposure represents an important component of the discussion below. 
 DNA damage response mechanisms of significance to low dose radiation exposure. 
 
Since DSBs represent the most biologically significant radiation induced lesion, I will 
focus on the DNA damage response (DDR) mechanisms responding to DSBs. Two 
conceptually distinct pathways contribute to the DSB-DDR; DSB repair pathways 
function to repair the damage whilst a DSB signaling pathway senses the DSB and 
activates a range of distinct responses, including cell cycle checkpoint arrest and/or 
apoptosis. Although largely independent, the repair and DSB signaling response overlap 
since the signaling pathway regulates at least some components of DSB repair. DNA non 
homologous end-joining (NHEJ) represents the major DSB repair mechanism with 
homologous recombination (HR) being an additional mechanism that functions in late 
S/G2 phase of the cell cycle (1).  
The process of NHEJ and its component proteins are shown in Figure 1. HR plays a 
minor role in repair of direct radiation induced DSBs but does have an important role in 
repairing DSBs that arise following replication of radiation induced lesions. Ataxia 
telangiectasia mutated (ATM) is a protein kinase that lies at the heart of the damage 
response signal transduction process that responds to DSBs (see Figure 2) (2). ATR, a 
related protein kinase, regulates a similar process that responds to replication fork stalling 
or other situations where single stranded DNA regions are generated. Although there is 
overlap between ATM and ATR, ATM is the major kinase that is activated by DSBs and 
thus will be the major focus here. ATM is rapidly recruited to DSB lesions most likely 
via the Mre11-Rad50-Nbs1 (MRN) complex (3). ATM is recruited as a dimer but 
following activation, undergoes autophosphorylation leading to monomerisation and full 
activation (4). An early step in the signaling cascade is phosphorylation of a histone H2A 
variant, H2AX, generating γ-H2AX (phosphorylated H2AX). A complex but ordered 
recruitment of “mediator” proteins then ensues, whose hierarchical and ordered assembly 
is just beginning to become understood (Fig 2) (see (5) for recent findings of the 
assembly process) . Currently, this process culminates in the retention of 53BP1 at the 
site of the DSB, although further downstream steps or components may yet be uncovered. 
The precise function of these proteins in ATM signaling is still not well understood but 
they appear to help to retain ATM at the DSB site and to serve, at least to some extent, to 
allow the signaling process to function in the face of the higher order chromatin structure 
of the DNA. Perhaps surprisingly, ATM activation and ATM-dependent phosphorylation 
events are only mildly impaired in cells lacking the mediator proteins, leading to the 
suggestion that they have an amplification role in ATM signaling (6). However, ATM 
and the mediator proteins are specifically required for the repair of a subset of DSBs 
representing those located within or close to heterochromatic regions (7). These DSBs are 
repaired with slow kinetics in control cells, consistent with the notion that they require 
more complex processing. 
 As mentioned above, ATM signaling results in activation of cell cycle checkpoint 
arrest and/or apoptosis as well as regulating a component of DSB repair (8). Cell cycle 
checkpoint activation is achieved in part by the activation via phosphorylation of the 
transducer kinase, Chk2, as well as by phosphorylating p53, a transcriptional regulator. 
Another transducer kinase, Chk1, can also be activated in an ATM-dependent manner 
following ATM-dependent resection at DSBs and subsequent activation of ATR (9). For 
a consideration of the impact of ATM signaling on survival and genomic stability, rather 
than focusing further on the interesting but complex signaling process, I will consider the 
end points of the process, namely cell cycle checkpoint arrest and apoptosis. Apoptosis 
represents an ordered suicidal process that results in the destruction of damaged cells. 
Apoptosis plays a major role in removing cells during certain developmental processes, 
such as during lymphocyte development, but appears also to be exploited by the damage 
response to remove damaged cells that might otherwise survive and lead to 
carcinogenesis. The significantly elevated carcinogenesis and resistance to DNA 
damaging agents of p53 defective mice or cells, respectively, attests to the importance of 
apoptosis in preventing the proliferation of damaged cells. However, not all cells undergo 
apoptosis. Cell cycle checkpoint arrest represents the activation of surveillance 
mechanisms at “checkpoints” in the cell cycle to prevent progression through the cell 
cycle until critical processes have been completed (10).  The process monitors DNA 
integrity for the presence of DSBs (via ATM) or single stranded regions of DNA (via 
ATR). Checkpoint arrest can occur at the G1/S and G2/M transition and during S phase. 
The process primarily aims to prevent either replication or mitosis in the presence of 
DNA damage. Cell cycle checkpoint arrest can be transient providing enhanced time for 
DSB repair or can be permanent, thereby functioning as an alternative to apoptosis to 
prevent the proliferation of damaged cells.  
 
Functional significance of the DSB DDR pathways. 
 
DSBs are a particularly harmful lesion because, if unrepaired, loss of genetic material and 
most likely cell death, will ensue following cell division or, of equal significance, if 
misrepaired, DSBs can lead to genomic rearrangements with the potential activation of 
tumour activating genes or the loss of tumour suppressor genes, both events contributing 
to carcinogenesis. It is, therefore, important to consider not only how the DDR pathways 
enhance cellular survival but additionally how they serve to limit genomic instability. 
Indeed, for a consideration of the impact of low dose exposure, how the DDR pathways 
maintain genomic stability may be more important than how they enhance survival. The 
important role of NHEJ in enhancing cellular survival is demonstrated by the dramatic 
radiation sensitivity of mutants that lack NHEJ proteins (11). Although NHEJ is often 
described as being an inaccurate process, NHEJ mutants display elevated radiation 
induced chromosome rearrangements as well as increased chromosome breaks indicating 
that, even though errors may arise during NHEJ, the process is efficient in limiting 
chromosome rearrangements. Cell cycle checkpoint arrest and apoptosis both play 
important roles in preventing the proliferation of damaged cells. Cell cycle checkpoint 
arrest also serves to increase the time for DSB repair, which can be particularly important 
for DSBs that are repaired with slow kinetics, a feature of DSBs induced by high linear 
energy transfer (LET) radiation. Failure to activate G2/M arrest after exposure to low 
doses of IR has been proposed to explain the phenomenon of low dose hypersensitivity, 
in which cells display relatively high sensitivity after exposure to low doses (less than 0.3 
Gy) compared to the predicted response based on survival to a slightly higher dose (12). 
Whilst this possibility provides evidence that cell cycle checkpoint arrest can enhance 
survival, the process likely exerts its major impact on maintaining genomic stability since 
progression of cells through mitosis or replication decreases the possibility of accurate 
repair, and enhances the potential for misrepair. Importantly, however, the available data 
suggests that checkpoint arrest and DSB repair mechanisms function co-operatively to 
minimize genomic instability (12).  This is most dramatically demonstrated in cell lines 
that lack ATM signalling, a process that impacts upon both DSB repair, cell cycle 
checkpoint arrest and apoptosis (13). Thus, ATM-defective cell lines display both high 
radiosensitivity and genomic instability. 
 
Insight gained from the analysis of DDR disorders. 
 
Significant defects in DSB DDR mechanisms have been described in patients conferring 
syndromes classified as DNA damage response disorders (see Table 1). Although such 
patients likely represent a subset of individuals with radiation hypersensitivity that 
manifests at low and high doses, the disorders are rare and normally associated with 
marked clinical characteristics, which frequently result in shortened life expectancy. 
Nevertheless, a consideration of the clinical features of these patients and the phenotype 
of cell lines derived from them is informative in considering whether more subtle, but 
more common, defects in the DDR pathways might confer genetic susceptibility to low 
dose radiation. 
 Ataxia telangiestasia (A-T) is the human disorder conferred by loss of ATM, with 
many patients having completely inactivating (ie null) mutations (8). A-T is a devastating 
disorder conferring progressive neurodegeneration leading to ataxia, a variable level of 
immunodeficiency and cancer predisposition. Nijmegen Breakage Syndrome (NBS), A-T 
like disorder (ATLD) and the recently described Riddle Syndrome are further disorders 
that impact upon ATM signaling with defects in Nbs1, Mre11 and RNF168, respectively 
(14-16). Interestingly, whilst NBS patients display growth and developmental delay but 
not progressive ataxia, ATLD patients manifest a less severe A-T phenotype. However, 
the MRN complex is essential (ie null mutations do not exist) and is also required for 
efficient ATR signaling. The different phenotypes of these patients likely reflects the 
nature of the hypomorphic mutations in the genes, which may impact upon some but not 
all of the functions of the MRN complex. Defects in four components of the NHEJ 
machinery have also been reported in patients, namely DNA ligase IV, XLF, Artemis and 
DNA-PKcs (17, 18). These patients are characterized by severe combined 
immunodeficiency (SCID) or milder combined immunodeficiency due to the role that 
NHEJ plays during the process of V(D)J recombination. Another striking feature of some 
of the NHEJ defective patients is microcephaly, growth delay and dysmorphic facial 
features. 
 Cell lines derived from any of these patients display marked radiosensitivity, both 
to acute higher dose exposure as well as, where studied, to low dose or dose rate exposure 
(19, 20). In some cases, patients have shown clinical radiosensitivity following 
radiotherapy (21). The question, therefore, arises whether such patients would show 
hypersensitivity to low doses of IR. It should be appreciated that the phenotype of these 
patients arises as a consequence of diminished repair or signaling of endogenously arising 
DSBs (or DSBs that arise from background irradiation in our environment). Therefore, a 
consideration of their phenotypes might provide clues to the potential impact of low dose 
radiation exposure, where low numbers of excess unrepaired DSBs may accumulate.  
A feature in common to these patients is cancer predisposition, with the most 
significant predisposition being to tumours of lymphoid origin. Paradoxically, the SCID 
conferred by more severe NHEJ defects precludes the onset of lymphoid tumours due to 
the diminished or absent T and B cells. However, in cases where residual T and B cells 
remain, lymphoid tumours are observed (17). This was strikingly shown in one LigIV 
syndrome patient who harboured a mild, hypomorphic mutation in DNA ligase IV that 
was not sufficiently severe to cause observable immunodeficiency (21). The patient, 
however, developed T cell leukaemia at age 14. The predisposition to lymphoid tumours 
could arise from a failure to adequately repair or respond to DSBs induced during 
immune development (V(D)J recombination or class switch recombination). Since the 
translocations that arise in these tumours require that two unrepaired DSBs rejoin 
incorrectly, it is likely that low dose radiation exposure will enhance lymphoid 
malignancy by increasing the background level of unrepaired DSBs. Such a possibility is 
consistent with the fact that radiation exposure enhances lymphoid malignancies. Similar 
predisposition to lymphoid malignancies is also observed in mouse models of these 
disorders. These findings provide strong, albeit indirect, evidence that these patients may 
show hypersensitivity to carcinogenesis following low dose radiation exposure. 
A further feature that is observed in some of the syndromes discussed above is 
microcephaly (17). The observed microcephaly occurs during embryonic development 
and is not progressive post birth. The analysis of wild type and LigIV syndrome mice (a 
mouse strain that, like the human patients, harbours a hypomorphic mutation in DNA 
ligase IV) suggests that the stem cells of the embryonic brain are dramatically radiation 
sensitive (Liu, unpublished observations). This, together with additional evidence, 
suggests that the embryonic developing brain may be particularly sensitive to exposure to 
low doses of radiation. 
In recent work, Dr. M. Harms-Ringdahl has observed that human fibroblasts 
undergo premature growth arrest or senescence following exposure to chronic low dose 
rate irradiation (5 or 15 mGy/h) (unpublished observations). In collaborative work with 
the Harms-Ringdahl laboratory, we have observed that cells from A-T, LigIV or Artemis 
patients undergo senescence or growth arrest prematurely following chronic low dose 
irradiation compared to control cell lines (data not shown). This was most strikingly 
observed in LigIV syndrome cell lines where exposure to 5 mGy/h conferred rapid 
inhibition of cellular growth. This raises the possibility that low dose radiation exposure 
may confer premature loss of proliferative potential in vivo as a result of DSB 
accumulation exceeding the capacity of the cellular repair machinery. The findings also 
suggest that the DSB DDR disorder patients show a heightened response. Consistent with 
this, studies examining the haematopoeitic stem cell (HSCs) numbers of LigIV syndrome 
mice provided strong evidence of diminished stem cell numbers with age as well as a 
reduced capacity to proliferate in grafting experiments compared to control HSCs (22). 
The evidence suggested that this was due to elevated unrepaired DSBs in the LigIV 
syndrome mice. Reduced stem cell proliferation potential was also observed in wild type 
mice following irradiation and by elevated levels of reactive oxygen species in ATM 
defective mice (23, 24). Together, these findings suggest that both radiation exposure to 
control mice or endogenously generated DSBs in DDR defective mice can inhibit the 
proliferation of HSCs. Whether low dose radiation exposure will confer a more marked 
impact has not yet been examined. Collectively, these studies raise the possibility that 
elevated levels of unrepaired DSBs may additionally confer a diminished capacity of 
stem cells to proliferate, which could confer stem cell depletion with age and/or 
premature ageing. 
 
Can minor defects or polymorphisms in DDR proteins confer low dose radiation 
hypersensitivity. 
 
As discussed above, individuals with DDR disorders are rare. The question, therefore, 
arises whether less impacting mutational changes or polymorphisms in these same genes 
confers hypersensitivity to low dose radiation exposure. It is possible that minor defects 
in the damage response proteins could impair the repair or processing of DSBs, thereby 
enhancing cell death and stem cell turnover. Perhaps, more importantly even a modest 
impairment of DDR protein function could potentially enhance the genomic 
rearrangements that can lead to carcinogenesis. This could arise via mis-repair of a 
radiation induced DSB or by increasing the possibility of an interaction between and 
endogenously generated DSB, such as a DSB generated during immune development, 
and a radiation induced DSB.  
Although the DNA damage response disorders are rare, heterozygous carriers of the 
strongly impacting mutational changes are, at least in some populations, present at up to 1 
% of the population. Studies with heterozygous mice and cell lines derived from them 
have provided increasing evidence that heterozygosity for damage response proteins can, 
at least when coupled with other genetic defects, confer a subtle phenotype including 
cancer predisposition. For example, heterozygosity for DNA ligase IV in a tumour prone 
mouse strain, ink4a/art-/-, results in an elevated frequency of soft-tissue sarcomas with 
clonal amplifications, deletions and translocations (25). Additionally, dermal fibroblasts 
established from Ku80 heterozygous mice had elevated chromosome breaks (26). In 
addition, epidemiological studies on NBS and A-T heterozygotes, which in the Slavic and 
Ashkenazi Jewish populations, respectively, are relatively frequent, have provided 
evidence for elevated cancer predisposition with the impact being compounded by the 
effect of cigarette smoking (27-31). Finally, cellular studies on A-T heterozygous cell 
lines have also provided evidence of a detectably impaired damage response, which in 
one case was detected as a hypersensitivity to low dose radiation (19, 20, 32). A further 
patient class that should be mentioned in this context are heterozygous carriers of Brca1 
or Brca2 mutations. Brca1 plays a role in ATM signaling and both proteins are required 
for HR. For these two genes, heterozygosity confers a marked predisposition to breast 
and ovarian cancer. Collectively, these and similar experiments suggest that even a two 
fold reduction in the levels of damage response proteins is sufficient to drive 
chromosomal rearrangements leading to carcinogenesis.  
The next question to consider is whether modest mutational changes in these 
damage response proteins, including polymorphic changes, can exert a two fold impact 
on function, without causing any overt features indicative of a damage response disorder. 
Patient 180BR was clinically normal but developed leukaemia at age 14 and subsequently 
dramatically overresponded to radiotherapy (21). A homozygous mutational change was 
identified in DNA ligase IV (R278H) which reduced activity by approximately 10 fold. 
Thus, even a 10 fold reduction in DNA ligase IV appears sufficient to preclude the 
pronounced immunodeficiency observed in LIG4 syndrome patients, although it was 
most likely causally related to the onset of leukaemia in the patient. Significantly, another 
LIG4 syndrome patient, who displayed marked immunodeficiency and developmental 
delay, was observed to harbour the same homozygous mutational change (R278H) as 
well as two closely linked polymorphic changes in DNA ligase IV. Strikingly, the 
activity of in vitro expressed DNA ligase IV carrying the linked polymorphisms was 
approximately two fold reduced compared to wild type DNA ligase IV and the impact of 
the polymorphisms on R278H DNA ligase IV was at least additive providing an 
explanation for their differing clinical features (33). This provides an example of a 
polymorphic change having a two fold impact on protein function and its potential impact 
on other genetic changes. Thus, an individual homozygous for this polymorphism would 
have a similar magnitude of reduced LigIV activity compared to a heterozygous carrier 
with a fully inactivating mutation in one allele. A further aspect that should be considered 
in this context is that some mutational changes exert a dominant negative impact on 
protein function. Thus, although a mutational change may only partially impair protein 
function, it may have the capacity to inhibit the activity of the wild type protein. This 
occurs frequently for p53 mutations observed in cancers, and may occur, for example, in 
the case of the common founder mutation observed in NBS patients. Such a dominant 
negative effect has also been reported in knock-in mice for a mutation in ATM observed 
in A-T patients (34, 35). 
In the examples given above the cancer predisposition of heterozygous carriers of 
mutations in damage response genes was observed to spontaneous cancers and we cannot 
assess whether there may have been a contribution from exposure to background 
radiation exposure. In considering the likely additive or compounding impact of low dose 
radiation exposure, it is important to consider the distinction between DSBs induced by 
the byproducts of endogenous metabolism versus radiation induced DSBs.  
Endogenously introduced DSBs can arise from reactive oxygen species (ROS) as well as 
during defined metabolic processes such as V(D)J recombination. Abundant data has 
shown that radiation damage can be more complex than such endogenously arising DSBs 
and as a consequence have an increased potential for misrepair. In this context, any level 
of radiation damage, and most importantly, any exposure to high LET radiation, could be 
considered to be distinct from endogenous damage. Given the significant role that the 
DDR proteins discussed above play in the response to radiation exposure, it is reasonable 
to argue that the impact for cancer induction caused by low dose radiation exposure will 
be at least additive to that arising from endogenously arising DSBs. The studies of Kato 
et al. showing elevated levels of unrepaired DSBs in fibroblasts derived from A-T 





Here, I have overviewed the significant role that the DDR proteins that respond to DSBs 
play in enhancing survival and maintaining genomic stability in response to DSB 
formation. The most significant processes in this context are those that function in DNA 
non-homologous end-joining, homologous recombination and ATM signaling. Low dose 
radiation exposure may not dramatically impact upon cell killing although it is possible 
that chronic low dose rate exposure could lead to depletion of certain stem cell 
compartments with age. However, a highly significant role that the DDR proteins play in 
response to low dose radiation is to maintain genomic stability, thereby limiting the 
potential for the chromosome rearrangements that can drive carcinogenesis. Thus, one 
class of individuals who are likely to display genetic predisposition to the harmful effects 
of low dose exposure will be those with severe mutations in the DSB-DDR proteins, as 
observed in the characterized DNA damage response disorders. Fortunately, such 
individuals are rare.  However, there is mounting evidence from mice and human studies 
that even a two fold reduction in the levels of such proteins as observed in heterozygous 
carriers can confer significant cancer predisposition. Further, I provide at least one 
example where polymorphic changes can provide a two fold impact on protein function. 
Given the known role of these proteins in maintaining genomic stability following 
radiation exposure, it is likely that individuals harbouring more modestly impacting 
mutations in the DSB-DDR genes have the potential to display a predisposition to cancer 
induction from low dose radiation exposure and may thus represent a genetically 
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Figure 1: The process of DNA non homologous end-joining. 
The first step of DNA NHEJ (1) involves the binding of the heterodimeric Ku protein to 
DNA ends. Many of the DNA ends caused by radiation damage may have associated 
base damage as shown by the triangle and star on the DNA ends. Ku is a basket shaped 
molecule and encircles the DNA. It also has the capacity to translocate along the DNA. 
The second step of the reaction (2) involves the recruitment of DNA-PKcs to Ku-bound 
DNA generating the DNA-PK complex. DNA-PKcs is a larger protein with a kinase 
domain at its C-terminus. Binding of DNA-PKcs to DNA-bound Ku activates its kinase 
activity. The role of the DNA-PK kinase activity is currently unclear but the protein 
undergoes autophosphorylation. There is mounting evidence that DNA-PK facilitates 
processing of the DNA ends. Finally, a ligation complex involving a complex of DNA 
ligase IV and Xrcc4, and the associated protein, XLF, effects the ligation step of the 
reaction (3) to generate intact DNA (4). 
 
Figure 2: The process of ATM signaling and mediator protein recruitment. 
Current evidence suggests that the Mre11/Rad50/Nbs1 (MRN) complex (shown in blue) 
represents the primary DSB sensor which recruits dimerised ATM to the DNA end (step 
1). This rapidly causes ATM monomerisation and activation. An early substrate of ATM 
is H2AX, a variant from of the histone, H2A. Phosphorylated H2AX is designated g-
H2AX. MRN is also associated with MDC1 (shown in red). ATM phosphorylation of 
MDC1/H2AX enhances the binding of MDC1.to H2AX allowing it to be stably 
maintained at the DNA end (step 2). This results in the recruitment of the ubiquitin 
ligase, RNF8 (step 3) and subsequently RNAF168, (step 4) which ubiquitinate H2A. This 
in turn promotes the recruitment and retention of 53BP1 (shown in pink) at the DSB end. 
Recent evidence has also suggested that Brca1 and Rap80 contribute to H2A 
ubiquitination, and help with 53BP1 retention at the DNA end.  Retention of 53BP1 
appears to be dispensable for ATM activation but helps to retain ATM at the DSB site to 




Overview of clinical disorders associated with defects in DNA double strand break 
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Mre11 ++ Mild A-T like features as for Nbs1 
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